StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)

Close on Nov 17, 2026Market cap $8.27BP/E –Yield –

Spyre Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Spyre Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$208.57M. For fiscal 2025 it was -$209.56M. The highest annual figure on record is -$8.89M in fiscal 2014.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$209.56M–
FY2024Dec 31, 2024-$208.57M–
FY2023Dec 31, 2023-$241.56M–
FY2022Dec 31, 2022-$83.21M–
FY2021Dec 31, 2021-$64.07M–
FY2020Dec 31, 2020-$80.49M–
FY2019Dec 31, 2019-$79.92M–
FY2018Dec 31, 2018-$45.17M–
FY2017Dec 31, 2017-$27.43M–
FY2016Dec 31, 2016-$21.77M–
FY2015Dec 31, 2015-$11.23M–
FY2014Dec 31, 2014-$8.89M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$61.25M–
Q3 FY2024Sep 30, 2024-$55.39M–
Q2 FY2024Jun 30, 2024-$44.15M–
Q1 FY2024Mar 31, 2024-$47.77M–
Q4 FY2023Dec 31, 2023-$45.91M–
Q3 FY2023Sep 30, 2023-$18.34M–
Q2 FY2023Jun 30, 2023-$158.89M–
Q1 FY2023Mar 31, 2023-$18.42M–
Q4 FY2022Dec 31, 2022-$18.78M–
Q3 FY2022Sep 30, 2022-$18.35M–
Q2 FY2022Jun 30, 2022-$22.05M–
Q1 FY2022Mar 31, 2022-$24.04M–
Q4 FY2021Dec 31, 2021-$20.03M–
Q3 FY2021Sep 30, 2021-$19.88M–
Q2 FY2021Jun 30, 2021-$6.31M–
Q1 FY2021Mar 31, 2021-$17.85M–
Q4 FY2020Dec 31, 2020-$22.41M–
Q3 FY2020Sep 30, 2020-$17.87M–
Q2 FY2020Jun 30, 2020-$21.34M–
Q1 FY2020Mar 31, 2020-$18.87M–
Q4 FY2019Dec 31, 2019-$21.80M–
Q3 FY2019Sep 30, 2019-$22.04M–
Q2 FY2019Jun 30, 2019-$18.52M–
Q1 FY2019Mar 31, 2019-$17.56M–
Q4 FY2018Dec 31, 2018-$15.23M–
Q3 FY2018Sep 30, 2018-$12.17M–
Q2 FY2018Jun 30, 2018-$9.60M–
Q1 FY2018Mar 31, 2018-$8.18M–
Q4 FY2017Dec 31, 2017-$6.56M–
Q3 FY2017Sep 30, 2017-$7.93M–
Q2 FY2017Jun 30, 2017-$6.66M–
Q1 FY2017Mar 31, 2017-$6.28M–
Q4 FY2016Dec 31, 2016-$5.51M–
Q3 FY2016Sep 30, 2016-$6.27M–

More Spyre Therapeutics figures

See a number that looks wrong?